


HARNESSING THE POWER OF HMGB-1, NEOPTERIN AND SIL-2R

Three essential biomarkers for immune activation



HARNESSING THE POWER OF **HMGB-1, NEOPTERIN AND SIL-2R**: THREE ESSENTIAL BIOMARKERS FOR IMMUNE ACTIVATION

The immune response is a coordinated process that involves a complex set of molecules and interrelated signaling pathways. The activation of these pathways results in the successful eradication of diseased cells and pathogens in individuals with healthy immune systems. In other cases, the immune system may be over-activated and result in autoimmune disease. Three key molecules that have been proven to play an essential role in this regulation and modulation of the immune response include High Mobility Group Box 1 (HMGB-1), neopterin (Np), and soluble Interleukin-2 receptor (sIL-2R).¹⁻¹⁵

What are the similarities and differences between these three musketeers of the immune system? When should we be measuring them, and how? They certainly have similarities in their functions, across a broad spectrum of immune-related conditions. All three are useful biomarkers for immune activation, and their roles can be summarized as follows (see also Fig. 1).

Inflammatory Mediators

HMGB-1 is a potent inflammatory mediator released by activated immune cells, acting as a late mediator of inflammation.¹ Neopterin is a byproduct of the GTP-metabolic pathway and is produced by activated macrophages/monocytes, acting as a marker of cellular immune activation, and sIL-2R, also released during immune activation, is considered a marker of T-cell activation and inflammation.^{2,3}

Biomarkers of Disease Activity

Elevated levels of HMGB-1, neopterin, and sIL-2R are observed in various inflammatory and autoimmune disorders, making them potential biomarkers for disease activity and severity.⁴⁻⁶

Prognostic Indicators

High concentrations of all three molecules have been associated with adverse outcomes and disease progression in conditions such as sepsis, cancer, and autoimmune diseases.⁷⁻⁹

Immune Regulation

HMGB-1 can act as a chemoattractant for immune cells and promote their activation and migration.¹⁰ Neopterin has been shown to modulate oxidative stress and apoptosis, as its contribution to immune regulation.¹¹ Finally, sIL-2R is involved in regulating T-cell proliferation and activation, playing a role in immune homeostasis.¹²

Therapeutic Targets

Strategies targeting HMGB-1, neopterin, and sIL-2R are all being explored as potential therapeutic approaches for various inflammatory and autoimmune disorders such as cancer, rheumatoid arthritis and multiple sclerosis.¹³⁻¹⁵

Does this mean we need to measure all three of these markers, all the time, or will one of them suffice? This will depend on the individual disease state that is being investigated. As a rule of thumb, all three molecules are proven markers for immune activation, so the researcher or clinician could start by correlating the disease they are studying, diagnosing, or treating, with the research that has been done in that area.

The second consideration is that if tests are being carried out in the clinic, as opposed to in the research environment, the 'tiebreaker' will be that the clinician needs to use a test that is IVD-compliant, as opposed to RUO (research use only). To enable us to choose the biomarker(s) to monitor the disease state, let us first look briefly at the research that has been done on each of them, before moving on to consider how we might measure them.



1. Inflammatory Mediators

HMGB-1: potent inflammatory mediator

Neopterin: marker of cellular immune activation

sIL-2R: marker of T-cell activation and inflammation



2. Biomarkers of Disease

Elevated levels observed in inflammatory and autoimmune disorders



3. Prognostic Indicators

Adverse outcomes and disease progression in sepsis, cancer, and autoimmune disease



4. Immune Regulation

HMGB-1: chemoattractant in immune cell activation and migration

Neopterin: modulator of oxidative stress and apoptosis

sIL-2R: regulator in T-cell proliferation and activation



5. Therapeutic Targets

Potential therapeutic targets in diseases such as cancer, rheumatoid arthritis and multiple sclerosis

Figure 1: High Mobility Group Box 1 (HMGB-1), neopterin (Np), and soluble Interleukin-2 receptor (sIL-2R): three key molecules that play an essential role in regulation and modulation of the immune response.

HMGB-1


Human HMGB-1 is essential in the cell's stress response, playing a major role in many infectious diseases, as well as ischemia, immune disorders, neurodegenerative diseases, and cancer.¹⁶ It has gained significant interest in recent years due to its role as a potential biomarker for measuring inflammation and immune system dysregulation. A more in-depth explanation of its mechanism of action can be found in the [Tecan Blog series](#), as applied to its role in COVID-19 infection.

HMGB-1 is a non-histone nuclear protein that can be released from cells during cellular stress, injury, or inflammation.¹⁷ Once released into the extracellular environment, it acts as a 'danger-associated molecular pattern' (DAMP) and can trigger inflammatory responses by binding to pattern recognition receptors (PRRs) on immune cells.¹⁸

Elevated levels of HMGB-1 have been specifically observed in rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, and inflammatory bowel disease (IBD), which are all considered to be auto-immune diseases.¹⁹ In rheumatoid arthritis, HMGB-1 levels in synovial fluid and serum correlate with disease activity and severity, making it a potential biomarker for disease progression and treatment response.²⁰ In SLE, HMGB-1 levels are elevated in both serum and urine, and its levels correlate with disease activity, organ damage, and the presence of specific autoantibodies.²¹

HMGB-1 has also been explored as a biomarker for sepsis, a life-threatening condition characterized by an overwhelming immune response to infection.²² Elevated HMGB-1 levels have also been associated with the development and progression of various cancers, including breast, lung, and colorectal cancers, potentially due to its role in promoting inflammation and tumor growth.²³

Key advantages of using HMGB-1 as a biomarker include its stability in biological fluids and its direct involvement in the inflammatory and immune responses underlying so many diseases. However, until now it has been difficult to establish standardized methods for measuring HMGB-1 levels and to validate its clinical utility as a diagnostic and prognostic biomarker across different diseases. We shall return to this later, as there are now ELISA tests available that allow us to standardize HMGB-1 assays, and thus enable the comparison of results between labs globally.



HMGB-1

- 'Danger' signal when released from cells
- Triggers inflammation
- Activates immune cells
- Promotes cytokine production

Use: monitoring of the immune response in disease

Figure 2: HMGB-1 plays a key role in the body's response to injury and infection.

Neopterin


Neopterin (Np) is a compound produced by macrophages and dendritic cells upon stimulation by interferon-gamma (IFN- γ), a cytokine released by activated T-cells and natural killer cells during cellular immune responses.^{24,25} Np, with the systematic name 2-amino-4-hydroxy-6-(D-erythro-1',2',3'-trihydroxypropyl)-pteridine, belongs to the class of pteridines.²⁶ This particular Np was first isolated in 1963 from bee larvae, worker bees, and royal jelly.²⁷⁻²⁹ Later, in 1967, Np was isolated in human urine by Sakurai and Goto for the first time.³⁰ It has since been extensively studied in wide-spectrum inflammatory diseases, including viral, bacterial, and parasite infections, cardiovascular diseases, autoimmune diseases, and malignant tumors.³¹⁻³⁷

Neopterin levels in body fluids, such as serum, urine, and cerebrospinal fluid (CSF), are elevated during various inflammatory and immune-mediated conditions.³⁸ High Np levels are observed in viral infections, including HIV, hepatitis B and C, and cytomegalovirus, reflecting the activation of the cellular immune response against these pathogens.²⁶

In autoimmune disorders like rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis, neopterin levels correlate with disease activity and severity, making it a potential biomarker for monitoring disease progression and treatment response.³⁹ Neopterin levels are also increased in certain malignancies, such as leukemia, lymphoma, and solid tumors, possibly due to the activation of immune cells by tumor antigens.⁴⁰

In allograft recipients, elevated neopterin levels may indicate acute rejection episodes or post-transplant infections, contributing to the monitoring of transplant outcomes.⁴¹ Neopterin has also been studied as a biomarker for cardiovascular diseases, where it is associated with an increased risk of adverse events and may reflect the underlying inflammatory processes contributing to atherosclerosis.⁴²

As with HMGB-1, the advantages of using neopterin as a biomarker include its stability in biological fluids, its direct link to cellular immune activation, and the availability of well-established analytical methods for its measurement. An easy and reliable go-to option for measuring neopterin is again ELISA, which is a sensitive, robust, and accurate solution for the quantification of neopterin, even in complex samples like serum, plasma, and urine.



Neopterin:

- Indicator of cellular immune system activation and oxidative stress
- Elevated during inflammatory and immune-mediated conditions e.g. rheumatoid arthritis, organ rejection

Use: early marker for immune reaction, present before antibody response

Figure 3: Neopterin is an early marker for immune activation.



sIL-2 receptor

Like HMGB-1 and neopterin, interleukin-2 (IL-2) is a key signaling molecule in the human immune system. IL-2 is a cytokine, one of a group of small, secreted proteins released by cells that have a specific effect on the interactions and communication between cells, helping regulate the body's natural response to infection, so that it can discriminate between foreign ('non-self') and 'self'.⁴³

IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes. The major sources of IL-2 are activated CD4+ T cells and activated CD8+ T cells.⁴³ On T-cell activation, the soluble form of the interleukin-2 receptor (sIL-2R) is secreted, or 'shed', so that higher than background concentrations of sIL-2R are found in patients suffering from many conditions associated with an ongoing immune response (see Fig. 4).⁴³

The quantification of soluble interleukin-2 receptor (sIL-2R) in serum or plasma in adults is used by clinicians to assess immune function *in vivo*, to investigate and manage a broad range of diseases.

Elevated levels of sIL-2R are observed in autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis, where it correlates with disease activity and severity.^{44,45} In SLE, higher sIL-2R levels also correlate with organ involvement, and the presence of specific autoantibodies.⁴⁶

In rheumatoid arthritis, sIL-2R levels in serum and synovial fluid are associated with joint inflammation and erosion, making it a useful biomarker for monitoring both disease progression and response to treatment.⁴⁷ sIL-2R has even been studied as a biomarker for transplant rejection, as its levels increase during acute rejection episodes in various organ transplants, including kidney, liver, and heart.⁴⁸

There is a direct correlation between sIL-2R level and certain hematological malignancies, such as hairy cell leukemia and adult T-cell leukemia/lymphoma, reflecting the proliferation of malignant T-cells.⁴⁹ Other immune-mediated diseases associated with increased levels of sIL-2R include sarcoidosis, biliary cirrhosis, chronic immune activation in common variable immunodeficiency (CVID) and hemophagocytic lymphohistiocytosis (HLH).⁵⁰⁻⁵⁴

Finally, in infectious diseases, sIL-2R levels may be elevated due to T-cell activation in response to pathogens, such as HIV, cytomegalovirus, and tuberculosis.⁵⁵

Advantages of using sIL-2R as a biomarker include its stability in biological fluids and its direct association with T-cell activation, a central process in many immune-mediated disorders. The relative stability of sIL-2R levels throughout adult life, and the minimal gender-related differences also help make sIL-2R an attractive biomarker.^{56,57} However, sIL-2R levels can be influenced by various factors, such as age, renal function, and concomitant medications, which should be considered when interpreting its levels.⁵⁸

Soluble IL-2 receptor levels are generally measured using enzyme-linked immunosorbent assay (ELISA), or chemiluminescent immunoassay (CLIA). Commercially available assays should be calibrated against the international reference standard NIBSC 97/600.

Population	Concentration	Level	Reference
Non-diseased individuals			
Adults >18yrs	Median: 339 [282.5–440.7] U/mL	Low	Halacli, B., et al. (2016). Journal of critical care, 35, 185–190.
Adults (21-55yrs)	Mean: 410 (SD: 186) U/mL	Low	Mariotti, S., et al. (1992) Clinical endocrinology, 37(5), 415–422
Adults, n=20 (age 29.5 ± 1.8yrs), men and women	Mean: 209 (SD: 25) U/mL	Low	Manoussakis, M. N., et al. (1992) Lupus, 1(2), 105–109.
Adults, n=70 (age 37–63yrs), men and women	Median: 1,028 pg/mL (Range: 263-2210)	Low	Schimmelpennink, M. C., et al. (2020) Expert review of respiratory medicine, 14(7), 749–756.
Diseased individuals			
Sepsis: HLH, n=10, adults	Median: 2,259.9 [971.8-8,180.8] U/mL	High	Halacli, B., et al. (2016). Journal of critical care, 35, 185–190.
Graves' Disease, n=61 men and women	Mean: 1,610 (SD: 962) U/mL	High	Mariotti, S., et al. (1992) Clinical endocrinology, 37(5), 415–422
Systemic Lupus Erythematosus, n=25, men and women	Mean: 682 (SD:115) U/mL	High	Manoussakis, M. N., et al. (1992) Lupus, 1(2), 105–109.
Rheumatoid Arthritis, n=41, men and women	Mean: 734 (SD: 101) U/mL	High	Manoussakis, M. N., et al. (1992) Lupus, 1(2), 105–109.
Sarcoidosis; n=104, men and women	Median: 5,534 pg/mL (Range: 1,351-55,000 pg/mL)	High	Schimmelpennink, M. C., et al. (2020) Expert review of respiratory medicine, 14(7), 749–756.
Löfgren Syndrome (acute form of sarcoidosis), n=17, men and women	Median: 5,682 pg/mL (Range: 560-36,000 pg/mL)	High	Schimmelpennink, M. C., et al. (2020) Expert review of respiratory medicine, 14(7), 749–756.

sIL-2R:

- Marker of T-cell activation
- Helps distinguish self from non-self
- Associated with infection, autoimmune diseases and inflammatory conditions

Use: measurable surrogate for T-cell activation *in vivo* as part of disease prognosis and management.

Figure 4: Soluble IL-2R is a reliable marker for the presence of an ongoing immune response.

For detail and further data, see Tecan article [Soluble interleukin-2 receptor in sickness and in health](#)

How do we measure these ‘three musketeers’ of the immune activation pathway?

We have now established that all three of these immunological markers, HMGB-1, neopterin, and sIL-2R indicate an ongoing immune response and that they could all theoretically be used to monitor a huge range of immune-mediated diseases: in effect, they can all be considered as universal or generic markers for immune activation. The researcher or clinician will then have to make a considered choice regarding which one(s) would be the most appropriate to the disease being studied, diagnosed or treated, according to the empirical evidence that is available in the literature and the commercially available tests.

All three markers can be reliably measured using immunoassays, usually ELISA, and the Tecan Blog articles describe the close correlation of ELISA assays with other available techniques, such as HPLC, RIA or mass spectrometry-related methods. Therefore, as ELISA is by far the simplest method to implement, let us now look at the tests that are available and consider how we might be able to scale and automate these ELISA tests for the most reproducible results, thus enabling their global standardization.

Choosing and implementing ELISAs for immunology biomarkers

There are manifold ELISA tests available for all three of our immune activation biomarkers (HMGB-1, neopterin, and sIL-2R), as can be seen by a simple search of the internet. However, most of them are for research use only (RUO), so even if their utility is proven in terms of research and basic empirical evidence as a marker for a specific disease, their long-term use cannot be assured in the clinical space, which requires the use of IVD-compliant tests. Secondly, most tests are designed to be implemented manually, where ideally, they would be easily automatable and scalable for maximum reproducibility and for inter-lab comparisons.

These are just a couple of the key criteria for using ELISA for measuring immune activation. A more complete checklist might include:

- Ready-to-use assay reagents – no dilution necessary
- Ready-to-use standard-curve reagents – no stock dilution needed
- Kit ready-calibrated against standard preparations and other methods
- Internal kit controls provided
- Easily automatable

Tecan ELISA kits can be run either manually, for initial testing, and validation in the case of IVD-compliant kits for clinical needs, or they can be automated, according to the precise needs of your lab in terms of standardization and throughput goals. Automation scripts are readily available and are so-called 'open system', so that they can be easily adapted to your automation platform, and Tecan can also work directly with you to implement this.

Several white papers and articles are available for further study, depending on whether you would like to learn more about the science behind these tests, or whether you are more interested in implementing ELISA in your lab, with or without automation (see Immunology Biomarker Resource list, page 9). For more information on ordering ELISA tests and ongoing promotions, [visit your country's website](#).

Tecan's open approach to IVDR and automation is paving the way for global standardization and automation of ELISA as the primary method for measuring immunology markers in clinical settings, opening up new possibilities for their use in future research as we continue to exploit their huge potential in diagnosing, treating and monitoring disease.

» Discover Tecan's wide range of products for immunology testing

TECAN RESOURCES FOR IMMUNE SYSTEM ACTIVATION MARKERS*

<https://www.tecan.com/blog/topic/diagnostics-biomarkers>

<https://lifesciences.tecan.com/immunoassays-elisa-for-automated-solutions>

HMGB-1

<https://www.tecan.com/blog/role-of-hmgb1-immune-response-to-viral-infection-sars-cov2-cytokine-storm-syndrome>

<https://www.tecan.com/blog/hmgb1-antibody-cellular-stress-response>

https://www.tecan.com/blog/gold_standard_elisa_for_measuring_hmgb1

<https://www.tecan.com/blog/how-to-measure-alarmin-hmgb1>

<https://ibl-international.com/hmgb1-express-elisa>

<https://www.tecan.com/tecan-journal/a-voyage-of-discovery-exploring-the-role-of-hmgb1-in-trauma-pathology>

Neopterin

<https://www.tecan.com/blog/neopterin-the-early-warning-indicator-that-could-make-all-the-difference>

<https://www.tecan.com/blog/considerations-for-choosing-your-neopterin-assay>

<https://ibl-international.com/neopterin>

S-IL2R

<https://www.tecan.com/blog/soluble-interleukin-2-receptor-a-critical-inflammatory-biomarker-comes-of-age>

<https://www.tecan.com/blog/soluble-interleukin-2-receptor-in-sickness-and-in-health>

<https://ibl-international.com/soluble-interleukin-2-receptor-elisa-ruo>

<https://ibl-international.com/sinterleukin-2-receptor-elisa-ce-ivdr>

<https://www.tecan.com/tecan-journal/measuring-sil-2r-levels-in-interstitial-lung-disease>

REFERENCES

- Andersson, U., Yang, H., & Harris, H. (2018). High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. *Seminars in immunology*, 38, 40–48. PubMed: <https://pubmed.ncbi.nlm.nih.gov/29530410/> DOI: <https://doi.org/10.1016/j.smim.2018.02.011>
- Murr, C., Fuih, L. C., Widner, B., Wirleitner, B., Baier-Bitterlich, G., & Fuchs, D. (1999). Increased neopterin concentrations in patients with cancer: indicator of oxidative stress?. *Anticancer research*, 19(3A), 1721–1728. PubMed: <https://pubmed.ncbi.nlm.nih.gov/10470106/>
- Rubin, L. A., & Nelson, D. L. (1990). The soluble interleukin-2 receptor: biology, function, and clinical application. *Annals of internal medicine*, 113(8), 619–627. PubMed: <https://pubmed.ncbi.nlm.nih.gov/2205142/> DOI: <https://doi.org/10.7326/0003-4819-113-8-619>
- Abdulahad, D. A., Westra, J., Bijzet, J., Limburg, P. C., Kallenberg, C. G., & Bijl, M. (2011). High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. *Arthritis research & therapy*, 13(3), R71. PubMed: <https://pubmed.ncbi.nlm.nih.gov/21548924/> DOI: <https://doi.org/10.1186/ar3332>
- Sucher, R., Schroecksnadel, K., Weiss, G., Margreiter, R., Fuchs, D., & Brandacher, G. (2010). Neopterin, a prognostic marker in human malignancies. *Cancer letters*, 287(1), 13–22. PubMed: <https://pubmed.ncbi.nlm.nih.gov/19500901/> DOI: <https://doi.org/10.1016/j.canlet.2009.05.008>
- Witkowska, A. M. (2005). On the role of sIL-2R measurements in rheumatoid arthritis and cancers. *Mediators of inflammation*, 2005(3), 121–130. PubMed: <https://pubmed.ncbi.nlm.nih.gov/16106097/> DOI: <https://doi.org/10.1155/MI.2005.121>
- Sunden-Cullberg, J., Norrby-Teglund, A., & Treutiger, C. J. (2006). The role of high mobility group box-1 protein in severe sepsis. *Current opinion in infectious diseases*, 19(3), 231–236. PubMed: <https://pubmed.ncbi.nlm.nih.gov/16645483/> DOI: <https://doi.org/10.1097/OI.qco.0000224816.96986.67>
- Murr, C., Widner, B., Wirleitner, B., & Fuchs, D. (2002). Neopterin as a marker for immune system activation. *Current drug metabolism*, 3(2), 175–187. PubMed: <https://pubmed.ncbi.nlm.nih.gov/12003349/> DOI: <https://doi.org/10.2174/1389200024605082>
- Witkowska, A. M., & Sadiq, S. (2019). Soluble IL-2 receptor as a biomarker for immune monitoring in multiple sclerosis. *Journal of Neuroimmunology*, 329, 93–98.
- Bianchi M. E. (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. *Journal of leukocyte biology*, 81(1), 1–5. PubMed: <https://pubmed.ncbi.nlm.nih.gov/17032697/> DOI: <https://doi.org/10.1189/jlb.0306164>
- Hoffmann, G., Wirleitner, B., & Fuchs, D. (2003). Potential role of immune system activation-associated production of neopterin derivatives in humans. *Inflammation research: official journal of the European Histamine Research Society ... [et al.]*, 52(8), 313–321. PubMed: <https://pubmed.ncbi.nlm.nih.gov/14504669/> DOI: <https://doi.org/10.1007/s00011-003-1181-9>
- Rubin, L. A., & Nelson, D. L. (1990). The soluble interleukin-2 receptor: biology, function, and clinical application. *Annals of internal medicine*, 113(8), 619–627. PubMed: <https://pubmed.ncbi.nlm.nih.gov/2205142/> DOI: <https://doi.org/10.7326/0003-4819-113-8-619>
- Mollica, L., Bours, V., & Feron, O. (2015). Anticancer activity of HMGB proteins and their derivatives. *Current Medicinal Chemistry*, 22(18), 2285–2293.
- Reibnegger, G., Egg, D., Fuchs, D., Günther, R., Hausen, A., Werner, E. R., & Wachter, H. (1986). Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. *Arthritis and rheumatism*, 29(9), 1063–1070. PubMed: <https://pubmed.ncbi.nlm.nih.gov/3753537/> DOI: <https://doi.org/10.1002/art.1780290902>
- Bielekova, B., Catalfamo, M., Reichert-Scriver, S., Packer, A., Cerna, M., Waldmann, T. A., McFarland, H., Henkart, P. A., & Martin, R. (2006). Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2/Ralpha-targeted therapy (daclizumab) in multiple sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, 103(15), 5941–5946. PubMed: <https://pubmed.ncbi.nlm.nih.gov/16585503/> DOI: <https://doi.org/10.1073/pnas.0601335103>
- Kang, R., Chen, R. et al. (2014). HMGB1 in health and disease. *Molecular aspects of medicine*, 40, 1–116. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/25010388/> DOI: <https://doi.org/10.1016/j.mam.2014.05.001>
- Chen, R., Kang, R., & Tang, D. The mechanism of HMGB1 secretion and release. *Exp Mol Med* 54, 91–102 (2022). PubMed: <https://pubmed.ncbi.nlm.nih.gov/35217834/> DOI: <https://doi.org/10.1038/s12276-022-00736-w>
- Das, N., Dewan, V., Grace, P. M., Gunn, R. J., Tamura, R., Tzarum, N., Watkins, L. R., Wilson, I. A., & Yin, H. (2016). HMGB1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia. *Cell reports*, 17(4), 1128–1140. PubMed: <https://pubmed.ncbi.nlm.nih.gov/27760316/> DOI: <https://doi.org/10.1016/j.celrep.2016.09.076>
- Harris, H. E., Andersson, U., & Pisetsky, D. S. (2012). HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. *Nature reviews. Rheumatology*, 8(4), 195–202. PubMed: <https://pubmed.ncbi.nlm.nih.gov/22293756/> DOI: <https://doi.org/10.1038/nrrheum.2011.222>
- Goldstein, R. S., Bruchfeld, A., Yang, L., Qureshi, A. R., Gallowitsch-Puerta, M., Patel, N. B., Huston, B. J., Chavan, S., Rosas-Ballina, M., Gregersen, P. K., Czura, C. J., Sloan, R. P., Sama, A. E., & Tracey, K. J. (2007). Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. *Molecular medicine (Cambridge, Mass.)*, 13(3–4), 210–215. PubMed: <https://pubmed.ncbi.nlm.nih.gov/17597834/> DOI: <https://doi.org/10.2119/2006-00108.Goldstein>
- Abdulahad, W. H., Lamprecht, P., & Kallenberg, C. G. (2011). T-helper cells as new players in ANCA-associated vasculitides. *Arthritis research & therapy*, 13(4), 236. PubMed: <https://pubmed.ncbi.nlm.nih.gov/21888687/> DOI: <https://doi.org/10.1186/ar3362>
- Angus, D. C., & van der Poll, T. (2013). Severe sepsis and septic shock. *The New England journal of medicine*, 369(9), 840–851. PubMed: <https://pubmed.ncbi.nlm.nih.gov/23984731/> DOI: <https://doi.org/10.1056/NEJMra1208623>
- Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007). Masquerader: high mobility group box-1 and cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*, 13(10), 2836–2848. PubMed: <https://pubmed.ncbi.nlm.nih.gov/17504981/> DOI: <https://doi.org/10.1158/1078-0432.CCR-06-1953>
- Müller, M. M., Curtius, H. C., Herold, M., & Huber, C. H. (1991). Neopterin in clinical practice. *Clinica chimica acta; international journal of clinical chemistry*, 201(1–2), 1–16. PubMed: <https://pubmed.ncbi.nlm.nih.gov/1790613/> DOI: [https://doi.org/10.1016/0009-8981\(91\)90019-9](https://doi.org/10.1016/0009-8981(91)90019-9)
- Fuchs, D., Hausen, A., Reibnegger, G., Werner, E. R., Dierich, M. P., & Wachter, H. (1988). Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. *Immunology today*, 9(5), 150–155. PubMed: <https://pubmed.ncbi.nlm.nih.gov/3076770/> DOI: [https://doi.org/10.1016/0167-5699\(88\)91203-0](https://doi.org/10.1016/0167-5699(88)91203-0)
- Murr, C., Widner, B., Wirleitner, B., & Fuchs, D. (2002). Neopterin as a marker for immune system activation. *Current drug metabolism*, 3(2), 175–187. PubMed: <https://pubmed.ncbi.nlm.nih.gov/12003349/> DOI: <https://doi.org/10.2174/1389200024605082>
- Rembold, H.; Buschmann, L. Struktur und Synthese des Neopterin. *Chem. Ber.* 1963, 96, 1406–1410.
- Hamerlinck, F.F. Neopterin: A Review. *Exp. Dermatol.* 1999, 8, 167–176.
- Rembold, H.; Buschmann, L. Untersuchungen Über Die Pteridine Der Bienenpuppe (Apis Mellifica). *Justus Liebigs Ann. Der Chem.* 1963, 662, 72–82. DOI: <https://doi.org/10.1002/jlac.19636620108>
- Sakurai, A., & Goto, M. (1967). Neopterin: isolation from human urine. *Journal of biochemistry*, 61(1), 142–145. PubMed: <https://pubmed.ncbi.nlm.nih.gov/6048965/> DOI: <https://doi.org/10.1093/oxfordjournals.jbchem.a128513>
- Schneider-Crease, I. A., Feder, J. A., Baniel, A., McCann, C., Haile, A. A., Abebe, B., Fitzgerald, L., Gomery, M. A., Simberloff, R. A., Petrie, Z. L., Gabriel, S., Dorny, P., Fashing, P. J., Nguyen, N., Bergman, T. J., Beehner, J. C., Snyder-Mackler, N., & Lu, A. (2022). Urinary neopterin reflects immunological variation associated with age, helminth parasitism, and the microbiome in a wild primate. *Scientific reports*, 12(1), 21307. PubMed: <https://pubmed.ncbi.nlm.nih.gov/36494454/> DOI: <https://doi.org/10.1038/s41598-022-25298-9>
- Rasmi, Y., Heidari, N., Kübra Kirboğa, K., Hatamkhani, S., Tekin, B., Alipour, S., Naderi, R., Farnamian, Y., & Akca, I. (2022). The importance of neopterin in COVID-19: The prognostic value and relation with the disease severity. *Clinical biochemistry*, 104, 1–12. PubMed: <https://pubmed.ncbi.nlm.nih.gov/35307400/> DOI: <https://doi.org/10.1016/j.clinbiochem.2022.03.002>
- Heneberk, O., Vernerova, A., Kujovska Krcmova, L., Wurfelova, E., & Radochova, V. (2022). Neopterin Levels in Periodontitis and after Nonsurgical Periodontal Therapy: Evaluation of Gingival Crevicular Fluid, Oral Fluid, Serum and Urinary Samples-A Case-Control Study. *Biomedicines*, 10(12), 3200. PubMed: <https://pubmed.ncbi.nlm.nih.gov/36551955/> DOI: <https://doi.org/10.3390/biomedicines10123200>
- Pink, R., Melichar, B., Tomanđl, J., Blažková, L., Trvdý, P. & Zapletalová, J. (2016). Salivary neopterin concentrations in patients with cancer of the oral cavity. *Pteridines*, 27(3–4), 53–58. DOI: <https://doi.org/10.1515/pterid-2015-0017>
- Dogheim, G. M., Amralla, M. T., & Werida, R. H. (2022). Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level. *Inflammopharmacology*, 30(5), 1617–1622. PubMed: <https://pubmed.ncbi.nlm.nih.gov/35876931/> DOI: <https://doi.org/10.1007/s10787-022-01028-5>
- Labouret, M., Trebossen, V., Ntorokou, A., Bartoli, S., Aubart, M., Auvin, S., Bader-Meunier, B., Baudouin, V., Corseri, O., Dingulu, G., Ducrocq, C., Dumaine, C., Elmaleh, M., Fabien, N., Faye, A., Hau, I., Hentgen, V., Kwon, T., Meinzer, U., Ouldali, N., ... Melki, I. (2024). Juvenile neuropsychiatric systemic lupus erythematosus: A specific clinical phenotype and proposal of a probability score. *Lupus*, 33(4), 328–339. PubMed: <https://pubmed.ncbi.nlm.nih.gov/38315109/> DOI: <https://doi.org/10.1177/09612033241229022>

37. Huber, C., Batchelor, J. R., Fuchs, D., Hausen, A., Lang, A., Niederwieser, D., Reibnegger, G., Swetly, P., Troppmair, J., & Wachter, H. (1984). Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. *The Journal of experimental medicine*, 160(1), 310-316. PubMed: <https://pubmed.ncbi.nlm.nih.gov/6429267/> DOI: <https://doi.org/10.1084/jem.160.1.310>
38. Hailemichael, W., Kiros, M., Akelew, Y., Getu, S., & Andualem, H. (2021). Neopterin: A Promising Candidate Biomarker for Severe COVID-19. *Journal of inflammation research*, 14, 245-251. PubMed: <https://pubmed.ncbi.nlm.nih.gov/33564258/> DOI: <https://doi.org/10.2147/JIR.S290264>
39. Mangoni, A. A., & Zinellu, A. (2023). A systematic review and meta-analysis of neopterin in rheumatic diseases. *Frontiers in immunology*, 14, 1271383. PubMed: <https://pubmed.ncbi.nlm.nih.gov/37799718/> DOI: <https://doi.org/10.3389/fimmu.2023.1271383>
40. Sucher, R., Schroecksnadel, K., Weiss, G., Margreiter, R., Fuchs, D., & Brandacher, G. (2010). Neopterin, a prognostic marker in human malignancies. *Cancer letters*, 287(1), 13-22. PubMed: <https://pubmed.ncbi.nlm.nih.gov/19500901/> DOI: <https://doi.org/10.1016/j.canlet.2009.05.008>
41. Reibnegger, G., Aichberger, C., Fuchs, D., Hausen, A., Spielberger, M., Werner, E. R., Margreiter, R., & Wachter, H. (1991). Posttransplant neopterin excretion in renal allograft recipients--a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. *Transplantation*, 52(1), 58-63. PubMed: <https://pubmed.ncbi.nlm.nih.gov/1858155/> DOI: <https://doi.org/10.1097/00007890-199107000-00012>
42. Sugioka, K., Naruko, T., Matsumura, Y., Shirai, N., Hozumi, T., Yoshiyama, M., & Ueda, M. (2010). Neopterin and atherosclerotic plaque instability in coronary and carotid arteries. *Journal of atherosclerosis and thrombosis*, 17(11), 1115-1121. PubMed: <https://pubmed.ncbi.nlm.nih.gov/20693747/> DOI: <https://doi.org/10.5551/jat.4606>
43. Liao, W., Lin, J. X., & Leonard, W. J. (2011). IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. *Current opinion in immunology*, 23(5), 598-604. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/21889323/> DOI: <https://doi.org/10.1016/j.coi.2011.08.003>
44. Razaqat, S., & Razaqat, S. (2023). Role of IL-2/IL-2 receptor in pathogenesis of autoimmune disorders: Genetic and therapeutic aspects. *World Journal of Medical Genetics*, 11(3), 28-38. DOI: <https://doi.org/10.5496/wjmg.v11.i3.28>
45. Neish, C., Charley, M., Fertig, N., Medsger, T., Jr, & Deng, J. S. (1993). Elevated serum soluble interleukin-2 receptor levels in subacute cutaneous lupus erythematosus. *Journal of dermatological science*, 5(3), 143-149. PubMed: <https://pubmed.ncbi.nlm.nih.gov/7694647/> DOI: [https://doi.org/10.1016/0923-1811\(93\)90761-d](https://doi.org/10.1016/0923-1811(93)90761-d)
46. Illei, G.G., Tackey, E., Lapteva, L. and Lipsky, P.E. (2004). Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. *Arthritis & Rheumatism*, 50: 2048-2065. PubMed: <https://pubmed.ncbi.nlm.nih.gov/15248202/> DOI: <https://doi.org/10.1002/art.20345>
47. Symons, J. A., Wood, N. C., Di Giovine, F. S., & Duff, G. W. (1988). Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. *Journal of immunology (Baltimore, Md.: 1950)*, 141(8), 2612-2618. PubMed: <https://pubmed.ncbi.nlm.nih.gov/3262665/>
48. Zucchelli, G. C., Clerico, A., De Maria, R., Carmellini, M., Di Stefano, R., Masini, S., Pilo, A., & Donato, L. (1990). Increased circulating concentrations of interleukin 2 receptor during rejection episodes in heart- or kidney-transplant recipients. *Clinical chemistry*, 36(12), 2106-2109. PubMed: <https://pubmed.ncbi.nlm.nih.gov/2253354/>
49. Murakami, J., Arita, K., Wada, A., Mihara, H., Origasa, H., Kigawa, M., Yasuda, I., & Sato, T. (2019). Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. *Molecular and clinical oncology*, 11(5), 474-482. PubMed: <https://pubmed.ncbi.nlm.nih.gov/31620278/> DOI: <https://doi.org/10.3892/mco.2019.1922>
50. Thi Hong Nguyen, C., Kambe, N., Kishimoto, I., Ueda-Hayakawa, I., & Okamoto, H. (2017). Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. *The Journal of dermatology*, 44(7), 789- 797. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/28295528/> DOI: <https://doi.org/10.1111/1346-8138.13792>
51. Peerlings, D., Mimpfen, M., & Damoiseaux, J. (2021). The IL-2-IL-2 receptor pathway: Key to understanding multiple sclerosis. *Journal of Translational Autoimmunity*, 100123. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/35005590/> DOI: <https://doi.org/10.1016/j.jtauto.2021.100123>
52. Barak, V., Selmi, C., Schlesinger, M., Blank, M., Agmon-Levin, N., Kalickman, I., Gershwin, M. E., & Shoenfeld, Y. (2009). Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. *Journal of autoimmunity*, 33(3-4), 178-182. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/19846277/> DOI: <https://doi.org/10.1016/j.jaut.2009.09.010>
53. Litzman, J., Nechvatalova, J., Xu, J., Ticha, O., Vlkova, M., & Hel, Z. (2012). Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia. *Clinical and experimental immunology*, 170(3), 321-332. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/23121673/> DOI: <https://doi.org/10.1111/j.1365-2249.2012.04655.x>
54. Lin, M., Park, S., Hayden, A., Giustini, D., Trinkaus, M., Pudek, M., Mattman, A., Schneider, M., & Chen, L. (2017). Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. *Annals of hematology*, 96(8), 1241-1251. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/28497365/> DOI: <https://doi.org/10.1007/s00277-017-2993-y>
55. Carcelain, G., et al. (2001). *Clinical Immunology*, 99(3), 286-294.
56. Rubin, L. A., & Nelson, D. L. (1990). The soluble interleukin-2 receptor: biology, function, and clinical application. *Annals of internal medicine*, 113(8), 619-627. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/2205142/> DOI: <https://doi.org/10.7326/0003-4819-113-8-619>
57. Taniguchi, T., & Minami, Y. (1993). The IL-2/IL-2 receptor system: a current overview. *Cell*, 73(1), 5-8. PubMed ID: <https://pubmed.ncbi.nlm.nih.gov/8462103/> DOI: [https://doi.org/10.1016/0092-8674\(93\)90152-g](https://doi.org/10.1016/0092-8674(93)90152-g)
58. Vanessa Alende-Castro, Manuela Alonso-Sampedro, Carmen Fernández-Merino, Bernardo Sopeña, Carmen Vidal, Francisco Gude & Arturo Gonzalez-Quintela (2023). Factors influencing serum concentrations of soluble interleukin-2 receptor: a general adult population study, *All Life*, 16:1, 2169958 DOI: <https://doi.org/10.1080/26895293.2023.2169958>

Product availability and regulatory status may vary across regions outside the EU depending on local country-specific regulation. Please consult your local Tecan office for more information. In USA: For Research Use Only, not for use in diagnostic procedures. The combined use of the assays, process script and instrument has to be validated individually on site by each laboratory.

.....
Australia +61 3 9647 4100 **Austria** +43 62 46 89 330 **Belgium** +32 15 42 13 19 **China** +86 21 220 63 206 **France** +33 4 72 76 04 80 **Germany** +49 79 51 94 170
Italy +39 02 92 44 790 **Japan** +81 44 556 73 11 **Netherlands** +31 18 34 48 17 4 **Nordic** +46 8 750 39 40 **Singapore** +65 644 41 886 **Spain** +34 93 595 25 31
Switzerland +41 44 922 89 22 **UK** +44 118 9300 300 **USA** +1 919 361 5200 **Other countries** +41 44 922 81 11
.....

Tecan Group Ltd. makes every effort to include accurate and up-to-date information within this publication, however, it is possible that omissions or errors might have occurred. Tecan Group Ltd. cannot, therefore, make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this publication. Changes in this publication can be made at any time without notice. All mentioned trademarks are protected by law. In general, the trademarks and designs referenced herein are trademarks, or registered trademarks, of Tecan Group Ltd., Männedorf, Switzerland. A complete list may be found at <http://www.tecan.com/trademarks>. Product names and company names that are not contained in the list but are noted herein may be the trademarks of their respective owners. For technical details and detailed procedures of the specifications provided in this document please contact your Tecan representative.

403026, 2024-06

Tecan is in major countries a registered trademark of Tecan Group Ltd., Männedorf, Switzerland.

© 2024 Tecan Trading AG, Switzerland, all rights reserved.

www.tecan.com

